Abstract
During the last 30 years, the definition of glaucoma as been revised to eliminate the inclusion of intraocular pressure. Open angle glaucoma is the second leading cause of blindness in the world, but the proportion of those with the disease who become blind is low. Diagnostic methods for glaucoma need improvement. The pathogenetic steps to loss of neurons in glaucoma are increasingly understood and nonpressure lowering therapies are on the horizon.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Drance SM . Doyne Memorial Lecture, 1975. Correlation of optic nerve and visual field defects in simple glaucoma. Trans Ophthalmol Soc UK 1975; 95: 288–296.
Foster PJ, Buhrmann R, Quigley HA, Johnson GJ . The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol 2002; 86: 238–242.
Sommer A, Tielsch JM, Quigley HA, Gottsch JD, Javitt J, Singh K . Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans: The Baltimore Eye Survey. Arch Ophthalmol 1991; 109: 1090–1095.
Sommer A . Doyne Lecture. Glaucoma: facts and fancies. Eye 1996; 10: 295–301.
Buhrmann RR, Quigley HA, Barron Y, West SK, Oliva MS, Mmbaga BBO . The prevalence of glaucoma in a rural east African population. Invest Ophthalmol Vis Sci 2000; 41: 40–48.
Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R . The prevalence of glaucoma in a population-based study of Hispanics: Proyecto Ver. Arch Ophthalmol 2001; 119: 1819–1826.
Weih LM, Nanjan M, McCarty CA, Taylor HR . Prevalence and predictors of open-angle glaucoma: results from the Visual Impairment Project. Ophthalmology 2001; 108: 1966–1972.
Hollows FC, Graham PA . Intra-ocular pressure, glaucoma, and glaucoma suspects in a defined population. Br J Ophthalmol 1966; 50: 570–586.
Anderson DR . Collaborative normal tension glaucoma study. Curr Opin Ophthalmol 2003; 14: 86–90.
Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M . Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268–1279.
Thylefors B, Negrel AD . The global impact of glaucoma. Bull World Health Organ 1994; 72: 323–326.
Quigley HA . The number of persons with glaucoma worldwide. Br J Ophthalmol 1996; 80: 389–393.
Foster PJ, Johnson GJ . Glaucoma in China: how big is the problem? Br J Ophthalmol 2001; 85: 1277–1282.
Foster PJ, Oen FT, Machin D, Ng TP, Devereux JG, Johnson GJ et al. The prevalence of glaucoma in Chinese residents of Singapore: a cross-sectional population survey of the Tanjong Pagar district. Arch Ophthalmol 2000; 118: 1105–1111.
Quigley HA, Friedman DS, Congdon NG . Possible mechanisms of primary angle-closure and malignant glaucoma. J Glaucoma 2003; 12: 167–180.
Ramakrishnan R, Nirmalan PK, Krishnadas R, Thulasiraj RD, Tielsch JM, Katz J et al. Glaucoma in a rural population of southern India: the Aravind comprehensive eye survey. Ophthalmology 2003; 110: 1484–1490.
Leske MC, Connell AM, Schachat AP, Hyman L . The Barbados Eye Study. Prevalence of open angle glaucoma. Arch Ophthalmol 1994; 112: 821–829.
Friedman DS, Wolfs RC, O'Colmain BJ, Klein BE, Taylor HR, West S et al. Eye Diseases Prevalence Research Group. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004; 122: 532–538.
Buhrmann R, unpublished data from the Kongwa Eye Survey.
Leske MC, Ederer F, Podgor M . Estimating incidence from age-specific prevalence in glaucoma. Am J Epidemiol 1981; 113: 606–613.
Quigley HA, Vitale S . Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 1997; 38: 83–91.
Mukesh BN, McCarty CA, Rait JL, Taylor HR, Mukesh BN, McCarty CA et al. Five-year incidence of open-angle glaucoma: the Visual Impairment Project. Ophthalmology 2002; 109: 1047–1051.
Leske MC, Connell AM, Wu SY, Nemesure B, Li X, Schachat A et al. Incidence of open-angle glaucoma: the Barbados Eye Studies. The Barbados Eye Studies Group. Arch Ophthalmol 2001; 119: 89–95.
Quigley HA, Tielsch JM, Katz J, Sommer A . The rate of progression in open-angle glaucoma. Am J Ophthalmol 1996; 122: 355–363.
Smith SD, Katz J, Quigley HA . Analysis of progressive change in automated visual fields in glaucoma. Invest Ophthalmol Vis Sci 1996; 37: 1419–1428.
Katz J, Gilbert D, Quigley HA, Sommer A . Estimating progression of visual field loss in glaucoma. Ophthalmology 1997; 104: 1017–1025.
Collaborative Normal-Tension Glaucoma Study Group. Natural history of normal-tension glaucoma. Ophthalmology 2001; 108: 247–253.
Wilson MR, Kosoko O, Cowan Jr CL, Sample PA, Johnson CA, Haynatzki G et al. Progression of visual field loss in untreated glaucoma patients and glaucoma suspects in St. Lucia, West Indies. Am J Ophthalmol 2002; 134: 399–405.
Chen PP . Blindness in patients with treated open-angle glaucoma. Ophthalmology 2003; 110: 726–733.
Hattenhauer MG, Johnson DH, Ing HH, Herman DC, Hodge DO, Yawn BP et al. The probability of blindness from open-angle glaucoma. Ophthalmology 1998; 105: 2099–2104.
Quigley HA . Current and future approaches to glaucoma screening. J Glaucoma 1998; 7: 210–219.
Tielsch JM, Katz J, Singh K, Quigley HA, Gottsch JD, Javitt J et al. A population-based evaluation of glaucoma screening: The Baltimore Eye Survey. Am J Epidemiol 1991; 134: 1102–1110.
Gottlieb LK, Schwartz B, Pauker SG . Glaucoma screening. A cost-effectiveness analysis. Surv Ophthalmol 1983; 28: 206–226.
Boivin JF, McGregor M, Archer C . Cost effectiveness of screening for primary open angle glaucoma. J Medical Screening 1996; 3: 154–163.
Quigley HA, Park CK, Tracey PA, Pollack IP . Community screening for eye disease by lay persons: the Hoffberger program. Am J Ophthalmol 2002; 133: 386–392.
Wolfs RC, Klaver CC, Ramrattan RS, van Duijn CM, Hofman A, de Jong PT . Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study. Arch Ophthalmol 1998; 116: 1640–1645.
Quigley HA, Buhrmann RR, West SK, Isseme I, Scudder M, Oliva MS . Long-term results of glaucoma surgery among participants in an east African population survey. Br J Ophthalmol 2000; 84: 860–864.
Nolan WP, Baasanhu J, Undraa A, Uranchimeg D, Ganzorig S, Johnson GJ . Screening for primary angle closure in Mongolia: a randomised controlled trial to determine whether screening and prophylactic treatment will reduce the incidence of primary angle closure glaucoma in an east Asian population. Br J Ophthalmol 2003; 87: 271–274.
Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 714–720.
Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E . Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003; 121: 48–56.
Coleman AL, Diehl DLC, Jampel HD, Bachorik PS, Quigley HA . Topical timolol decreases plasma high-density lipoprotein cholesterol level. Arch Ophthalmol 1990; 108: 1260–1263.
Caprioli J, Miller JM . Optic disc rim area is related to disc size in normal subjects. Arch Ophthalmol 1987; 105: 1683–1685.
Varma R, Tielsch JM, Quigley HA, Hilton SC, Katz J, Spaeth GL et al. Race-, age-, gender-, and refractive error-related differences in the normal optic disc. Arch Ophthalmol 1994; 112: 1068–1076.
Ong LS, Mitchell P, Healey PR, Cumming RG . Asymmetry in optic disc parameters: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 1999; 40: 849–857.
Schwartz GF, Reardon G, Mozaffari E . Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol 2004; 137(Suppl 1): S13–S16.
Gurwitz JH, Glynn RJ, Monane M, Everitt DE, Gilden D, Smith N et al. Treatment for glaucoma: adherence by the elderly. Am J Public Health 1993; 83: 711–716.
Gurwitz JH, Yeomans SM, Glynn RJ, Lewis BE, Levin R, Avorn J . Patient noncompliance in the managed care setting. The case of medical therapy for glaucoma. Med Care 1998; 36: 357–369.
Kosoko O, Quigley HA, Vitale S, Enger C, Kerrigan LA, Tielsch JM . Risk factors for non-compliance with glaucoma follow-up visits. Ophthalmology 1998; 105: 2105–2111.
Jampel HD . Target pressure in glaucoma therapy. J Glaucoma 1997; 6: 133–138.
Quigley HA, Addicks EM, Green WR, Maumenee AE . Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Arch Ophthalmol 1981; 99: 635–649.
Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ . Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci 1995; 36: 774–786.
Kerrigan LA, Zack DJ, Quigley HA, Smith SD, Pease ME . TUNEL-positive ganglion cells in human primary open angle glaucoma. Arch Ophthalmol 1997; 115: 1031–1035.
Pease ME, McKinnon SJ, Quigley HA, Kerrigan-Baumrind LA, Zack DJ . Obstructed axonal transport of the neurotrophin receptor TrkB in experimental glaucoma. Invest Ophthalmol Vis Sci 2000; 41: 764–774.
Martin KRG, Quigley HA, Zack DJ, Levovitch-Verbin H, Kielczewski J, Valenta D et al. Gene therapy with brain-derived neurotrophic factor protects retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci 2003; 44: 4357–4365.
McKinnon SJ, Lehman DM, Tahzib NG, Ransom NL, Reitsamer HA, Liston P et al. Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol Ther 2002; 5: 780–787.
Quigley HA, Brown A, Dorman-Pease ME . Alterations in elastin of the optic nerve head in human and experimental glaucoma. Br J Ophthalmol 1991; 75: 552–557.
Maingret F, Fosset M, Lesage F, Laxdunski, Honore E . TRAAK is a mammalian neuronal mechano-gated K+ channel. J Biol Chem 1999; 274: 1381–1387.
Neufeld AH, Sawada A, Becker B . Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc Natl Acad Sci USA 1999; 96: 9944–9948.
Hare W, WoldeMussie E, Lai R, Ton H, Ruiz G, Feldmann B et al. Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey. Surv Ophthalmol 2001; 45(Suppl 3): S284–S289.
Schwartz M . Neurodegeneration and neuroprotection in glaucoma: development of a therapeutic neuroprotective vaccine: the Friedenwald lecture. Invest Ophthalmol Vis Sci 2003; 44: 1407–1411.
Levkovitch-Verbin H, Quigley HA, Kerrigan-Baumrind LA, D'Anna S, Kerrigan DF, Pease ME . Optic nerve transection in monkeys may result in secondary degeneration of retinal ganglion cells. Invest Ophthalmol Vis Sci 2001; 42: 975–982.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Quigley, H. New paradigms in the mechanisms and management of glaucoma. Eye 19, 1241–1248 (2005). https://doi.org/10.1038/sj.eye.6701746
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.eye.6701746
Keywords
This article is cited by
-
Mechanobiological responses of astrocytes in optic nerve head due to biaxial stretch
BMC Ophthalmology (2022)
-
Tolerability and efficacy of bimatoprost 0.01Â % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01Â % (APPEAL Taiwan) study
BMC Ophthalmology (2016)
-
A Population-based survey of the prevalence and types of glaucoma in Nigeria: results from the Nigeria National Blindness and Visual Impairment Survey
BMC Ophthalmology (2015)
-
Bimatoprost 0.01% in treatment-naïve patients with open-angle glaucoma or ocular hypertension: an observational study in the Korean clinical setting
BMC Ophthalmology (2014)
-
An evolutionary perspective on health innovation systems
Journal of Evolutionary Economics (2009)
